Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application ...

Stock analysts at Leerink Partnrs lowered their FY2025 earnings estimates for MoonLake Immunotherapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with ...

Designing Life with AI" is a cross-disciplinary MAKE project in which EPFL students get a chance to explore the research ...

One of the removed drug candidates, SAR445611, is an anti-CX3CR1 nanobody that Sanofi was developing in an inflammatory indication. The second jettisoned molecule is SAR444200, a GPC3-based ...

Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.

GTB-3650 is GT Biopharma’s wholly owned second-generation TriKE. It utilizes camelid nanobody technology, with the potential to improve potency and enhance binding affinity. The Phase 1 dose ...

For starters, it is not a traditional IgG antibody or heavy-chain only antibody. It is instead a Nanobody, which is a single-domain antibody that has three VHH domains. The best way to show that ...

Each year, over two million people fall victim to snakebites, resulting in more than 100,000 fatalities and 300,000 severe disabilities, according to the World Health Organization. These alarming ...

MoonLake Immunotherapeutics, a rising star in the biotech world, has emerged as a growing player in Cambridge’s biotech ...